New York, NY, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Following a challenge submitted by Pfizer, Inc., BBB National Programs’ National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enforcement action for failure to participate in the National Advertising Division (NAD) inquiry. Pfizer and BridgeBio sell prescription medication to treat transthyretin amyloid cardiomyopathy, a progressive and fatal disease caused by the buildup of a protein called ...